Fluvoxamine for the treatment of COVID-19. | Lancet Glob Health;10(3): e329, 2022 03. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

WHO COVID-19 Research Database

News/Update/Help

Advanced Search

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

Fluvoxamine for the treatment of COVID-19.

Boulware, David R; Abassi, Mahsa.

Boulware DR; Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN 55417, USA. Electronic address: boulw001@umn.edu.
Abassi M; Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN 55417, USA.

Lancet Glob Health ; 10(3): e329, 2022 03.

Article in English | MEDLINE | ID: covidwho-1683795

Subject(s)

COVID-19 Drug Treatment; Fluvoxamine; Fluvoxamine/therapeutic use; Humans; SARS-CoV-2

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Fluvoxamine / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Lancet Glob Health Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Fluvoxamine / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Lancet Glob Health Year: 2022 Document Type: Article